Tuberculosis Update. Topics to be Addressed
|
|
- Amberlynn Beasley
- 6 years ago
- Views:
Transcription
1 Tuberculosis Update Robert M. Jasmer, M.D. University of California, San Francisco TB Control Section, San Francisco Department of Public Health Topics to be Addressed TB in the USA Screening recommendations Blood tests for TB infection Treatment and monitoring Audience participation questions Reported TB Cases United States, No. of Cases 28,000 26,000 24,000 22,000 20,000 18,000 16,000 14,000 12,000 10, Year 1
2 A Tale of Two TBs Tuberculosis Screening Flowchart At-risk person Interferon-Gamma Assay (or TST) + symptom review Negative Positive Chest X-ray Treatment not indicated Normal Candidate for Rx of latent TB Abnormal Evaluate for active TB 2
3 Goals of Targeted Screening for Latent TB Infection Identify recently acquired TB infection Identify those who are at increased risk of developing active TB once infected Risk of Infection Contacts of infectious TB cases Foreign-born persons from TB endemic countries Healthcare workers Correctional facilities (inmates and staff) Nursing homes Long-term care facilities Renal dialysis units Medically underserved groups Risk of Progression HIV infection and other medical conditions Individuals with abnormal chest X-ray compatible with past TB (high rate of reactivation: 10% per year) Infants and children <5 yrs of age (sentinels of transmission) 5% risk of disease in first 2 years among contacts/converters 3
4 Which of the following persons should NOT be screened for TB? 1. Insulin-requiring diabetic 2. End-stage renal disease pt on dialysis 3. Rheumatoid arthritis pt on chronic prednisone and methotrexate 4. COPD pt on multiple inhalers 5. New immigrant to the US from India Which of the following persons should NOT be screened for TB? 1. Insulin-requiring diabetic 2. End-stage renal disease pt on dialysis 3. Rheumatoid arthritis pt on chronic prednisone and methotrexate 4. COPD pt on multiple inhalers 5. New immigrant to the US from India Risk of Progression (2) Medical conditions: Immunosuppression Lymphoma, leukemia Injection drug use Diabetes Malnutrition Renal failure Silicosis Alcoholism Immunosuppressive agents: Steroids Cancer chemotherapy Cyclosporine New: Tumor necrosis agents -Etanercept (Enbrel ) -Infliximab (Remicade ) -Adalimumab (Humira TM ) 4
5 Evaluation of LTBI" Calcified Granulomas " Evaluation of LTBI:" Stable Fibrotic Lesions" Diagnosis of Latent Tuberculosis Infection TB Skin Test (TST) QuantiFERON Blood Test (QFT) or ELISPOT T-SPOT TB Test 5
6 SCREENING FOR LTBI Tuberculin Skin Test 5 TU of PPD Read at hrs False positives Non-tuberculous mycobacteria Recent BCG vaccination Interpretation depends on person s risk factors Tuberculin Skin Test Interpretation: CDC/ATS Cut-Off Points > 5 mm HIV co-infection Immune compromise Recent contact to TB Suspected disease > 10 mm Foreign-born from a HR country Drug users Living in HR congregate setting Specific HR groups Children < 4 yrs old (AAP) >15 mm All others (low risk groups) Why did you test? Tuberculin Skin Testing Boosting Induration (mm)" 20" 15" 10" 5" 14 mm" 11 mm" 12 mm" 0" 0 " 5 " 10 " 15 " 20 " 30 " 31" Infection" TST" TST" TST" TST" Years" 6
7 Interferon-Gamma Assays: The First Alternative to the Tuberculin Test Interferon-γ release assays have emerged as the only alternative to the tuberculin test QuantiFERON-TB (Cellestis, Australia) T-SPOT-TB (Oxford Immunotec, UK) Interferon-γ assays measure cell-mediated immunity by quantifying IFN-γ released from sensitized T cells in whole blood/pbmcs incubated with TB antigens Interferon vs. TST In vitro Multiple antigens No boosting 1 patient visit Minimal inter-reader variability Results in 1 day Stimulate w/i 12 hrs In vivo Single antigen Boosting 2 patient visits Inter-reader variability Results in 2-3 days Read in hrs Advances in IFN-γ Technology Early assays employed PPD (same specificity problems as the TST) Newer assays (e.g., QFT-Gold) employ TB-specific antigens: ESAT-6 and CFP-10 Proteins encoded within the region of difference 1 of M. tuberculosis Not shared with the BCG sub-strains and most NTM species (except: M. kansasii, M. szulgai, M. marinum) 7
8 Species Specificity of ESAT-6 and CFP-10 Tuberculosis complex ESAT Antigens CFP M tuberculosis + + M africanum + + M bovis + + BCG substrain gothenburg - - moreau - - tice - - tokyo - - danish - - glaxo - - montreal - - pasteur - - Environmental strains Antigens ESAT CFP M abcessus - - M avium - - M branderi - - M celatum - - M chelonae - - M fortuitum - - M gordonii - - M intracellulare - - M kansasii + + M malmoense - - M marinum + + M oenavense - - M scrofulaceum - - M smegmatis - - M szulgai + + M terrae - - M vaccae - - M xenopi - - QuantiFERON-TB Gold In-Tube Add 1 ml of blood to each of the 3 tubes Incubate for hours at 37, then do ELISA Which of the following is the best way to rule out active TB (e.g., pre-hospital admission)?: 1. Tuberculin skin test 2. QuantiFERON-TB test 3. Chest X-ray 4. Symptom checklist (e.g cough/sweats/weight loss) 5. Call Dr. Oz on the Oprah TV show 8
9 Which of the following is the best way to rule out active TB (e.g., pre-hospital admission)?: 1. Tuberculin skin test 2. QuantiFERON-TB test 3. Chest X-ray 4. Symptom checklist (e.g cough/sweats/weight loss) 5. Call Dr. Oz on the Oprah TV show Sensitivity of QuantiFERON-TB Gold Test Pooled sensitivity of TST: 77%" Pai et al Clin Infect Dis 2007;44:74" Current Guidelines for Using Interferon- Gamma Release Assays for TB Recommended for use in ALL circumstances in which the tuberculin skin test is currently used Includes contact investigations, immigrant evaluation, surveillance (e.g. healthcare workers) Mazurek et al MMWR 2005;54:15" 9
10 QFT and Contact Investigation Expect maximum benefit: Populations with poor return rates (homeless) Foreign-born with high background prevalence of BCG vaccination Example: SF SRO hotel drug-resistance investigation Prior QFT results easy to track down in database 9/31 converters found! (6 QFT conversions and 1 case found) 4 negative TSTs positive QFT 2 negative QFTs positive QFT 3 negative TSTs positive TST Discordant Results: One Approach When pre-test probability is HIGH: if either TST or QFT is positive, consider as infected When pre-test probability is LOW (no risk factors for progression): Use QFT to improve the specificity of the TST If both TST and QFT testing are done, draw blood before doing TST to avoid sensitization Future Use of QuantiFERON-TB Testing 10
11 ATS/CDC Guidelines for Latent TB Infection Rating HIV- HIV+ Isoniazid for 9 months AII AII Rifampin for 4 months BII BIII Rifampin/pyrazinamide DII DII for 2 months (daily) Rifampin/pyrazinamide DII DIII for 2 months (twice-weekly) Ratings Guide! A=Strong evidence of efficacy!i=randomized trial! B=Moderate evidence!!ii=cohort/case control! C=Insufficient evidence!iii=expert opinion" AJRCCM 2000;161:221 MMWR 2003;52:735" Treatment of Latent TB Infection: Age is NOT an Issue No more 35 year old cut-off Treat irrespective of age! Why? 1) Focus is on those at increased risk of either recent infection or progression to active TB, so the benefits exceed the risk 2) Risk of hepatitis is much less now Duration of INH Therapy Stable Fibrotic Lesions Population Duration Reduction in TB All participants INH 12 mo 75% INH 6 mo 65% INH 3 mo 21% Completer/compliers INH 12 mo 93% INH 6 mo 69% INH 3 mo 31%!!!!! Int Union Agst TB. Bull WHO 1982;60:555" 11
12 Treatment of Latent TB Infection How long is enough? 5" 4" Calculated curve" Calculated values" Observed values" Lower TB rates among those who took 0-9 mo! Cases per 100" 3" 2" 1" 0" 0 "6 "12 " 18 " 24" Months of Treatment" No extra increase among those who took >9 mo! Comstock Int J Tuberc Lung Dis. 1999;10:847! New TB Guidelines for INH A Numbers Game HIV Co-Infection Children 9 Prior TB on CXR (TB-4) Regular Folks Treatment of LTBI" Stable Fibrotic Lesions" 12
13 30 year old woman with TST 12 mm and no symptoms What would you do next? 1. Collect 3 sputum for AFB smear/cultures 2. Begin treatment for latent TB infection with INH 3. Repeat the TST 4. Repeat the radiograph in 6 months What would you do next? 1. Collect 3 sputum for AFB smear/cultures 2. Begin treatment for latent TB infection with INH 3. Repeat the TST 4. Repeat the radiograph in 6 months 13
14 After 2 months of INH/RIF/EMB/PZA Which is the best next step? 1. Obtain a chest CT scan 2. Continue multidrug therapy for TB 3. Perform a fine-needle aspiration of the nodule 4. Refer for bronchoscopy to obtain better specimens Which is the best next step? 1. Obtain a chest CT scan 2. Continue multidrug therapy for TB 3. Perform a fine-needle aspiration of the nodule 4. Refer for bronchoscopy to obtain better specimens 14
15 Treatment of Culture-Negative and Inactive Tuberculosis Treatment of Latent TB in Special Situations Intermittent dosing: always Directly Observed Contacts of INH-resistant TB: 4-6 months of rifampin (longer for children and immunocompromised) Use rifabutin in HIV-infected patients on protease inhibitors For persons intolerant of INH, use 4 months of rifampin Monitoring Patients Baseline laboratory testing not needed except for: 1) HIV infection 2) pregnancy 3) hx of liver disease/heavy EtOH use Evaluate monthly for: 1) adherence 2) symptoms of hepatitis 15
16 Isoniazid-Induced Hepatitis N=13,838! N=11,141! Age (yr)!!hepatitis!!cases/1000" Age (yr)!!hepatitis!!cases/1000" < 20 " " 0.0" " " 3.0" " " 12.0" " " 23.0" > 64 " " 8.0" 0-14 " " 0.0 " " " 0.8" " " 2.1" 65 " " 2.8" Kopanoff et al. Am Rev Resp Dis 1976;117:991" Nolan CL et al. JAMA 1999;281:1014" Future Treatment for Latent TB Infection? Tuberculosis Trials Consortium Study 26 Prospective, randomized phase III study Compares the effectiveness of 3 months of weekly rifapentine and INH to 9 months of daily INH Eligible patients: HIV-infected, infected contacts, tuberculin converters, and radiographic evidence of prior TB 8,00 enrolled, results expected in 2011" TB will remain a primary care issue until better control is established outside of the U.S. The specificity of the new blood test for TB is an advance in our ability to accurately diagnose LTBI 9 months now preferred for isoniazid Questions? Call the TB Warmline at
Contracts Carla Chee, MHS May 8, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Contracts Carla Chee, MHS May 8, 2012 Carla Chee, MHS has the following disclosures to make: No conflict of interests No relevant
More informationAdvanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014
Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lisa Armitige, MD, PhD August 13, 2014 Lisa Armitige,
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2018 Bob Belknap M.D. Director, Denver Metro TB Program No Disclosures Objectives be able to describe: 1. Who should get tested
More informationDiagnosis and Medical Management of LTBI
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Diagnosis and Medical Management of LTBI Barbara Seaworth, MD December 8, 2009 CLINICAL DIAGNOSIS AND MANAGEMENT OF LATENT TB INFECTION Barbara
More informationTuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)
Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA) April 2019 Bob Belknap M.D. Director, Denver Metro TB Program Disclosures No relevant financial relationships Objectives Be able to
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Microbiology Epidemiology Common disease presentations Diagnosis of active
More informationMycobacterial Infections: What the Primary Provider Should Know about Tuberculosis
Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Diagnosis of active TB Screening
More informationMaking the Diagnosis of Tuberculosis
Making the Diagnosis of Tuberculosis Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Testing for TB Infection Targeted Testing: Key Points Test only if plan for ensuring treatment De-emphasizes
More informationWhat the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB
What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening
More informationTargeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University
Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University Tuberculosis Estimates USA World Infection 15,000,000 2,000,000,000
More informationTB Prevention Who and How to Screen
TB Prevention Who and How to Screen 4.8.07. IUATLD 1st Asia Pacific Region Conference 2007 Dr Cynthia Chee Dept of Respiratory Medicine / TB Control Unit Tan Tock Seng Hospital, Singapore Cycle of Infection
More informationTB Nurse Case Management San Antonio, Texas March 7 9, Clinical Diagnosis and
TB Nurse Case Management San Antonio, Texas March 7 9, 2012 Clinical Diagnosis and Management of LTBI Lynn Horvath, MD March 7, 2012 Lynn Horvath, MD has the following disclosures to make: No conflict
More informationTB Intensive Tyler, Texas December 2-4, 2008
TB Intensive Tyler, Texas December 2-4, 2008 Interferon Gamma Releasing Assays: Diagnosing TB in the 21 st Century Peter Barnes, MD December 2, 2008 TOPICS Use of interferon-gamma release assays (IGRAs)
More informationApproaches to LTBI Diagnosis
Approaches to LTBI Diagnosis Focus on LTBI October 8 th, 2018 Michelle Haas, M.D. Associate Director Denver Metro Tuberculosis Program Denver Public Health DISCLOSURES I have no disclosures or conflicts
More informationCHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]
CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT] QUESTION: : Which children in the United States should get a tuberculin skin test? Do questionnaires really work? Jeffrey
More informationTB in Corrections Phoenix, Arizona
TB in Corrections Phoenix, Arizona March 24, 2011 Treatment of Latent TB Infection Renuka Khurana MD, MPH March 24, 2011 Renuka Khurana, MD, MPH has the following disclosures to make: No conflict of interests
More informationTransmission and Pathogenesis of Tuberculosis
Transmission and Pathogenesis of Tuberculosis 2011 John Bernardo, M.D. Pulmonary Center Boston University School of Medicine Massachusetts Department of Public Health Division of TB Prevention and Control
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director, SF and North Coast AETC March 13, 2014 ACCREDITATION STATEMENT:
More informationATS/CDC Guidelines for Treating Latent TB Infection
TB Intensive Tyler, Texas June 2-4, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy R. Aksamit, MD June 2, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis Intensive University of
More informationLatent TB Infection (LTBI)
Latent TB Infection (LTBI) Diagnosis & Treatment of Latent TB Infection (LTBI) Amee Patrawalla MD MPH Assistant Professor UMDNJ-New Jersey Medical School Infection with Mycobacterium tuberculosis without
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Tuberculosis Pathogenesis and Treatment of Latent TB Infection Lynn Horvath, MD November 11, 2014 Lynn Horvath, MD has the following disclosures to
More informationDiagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010
TB Nurse Case Management Lisle, Illinois April 27-28, 28 2010 Diagnosis and Medical Case Management of Latent TB Infection Bryan Rock, MD April 27, 2010 DIAGNOSIS AND MANAGEMENT OF LATENT TUBERCULOSIS
More informationUsing Interferon Gamma Release Assays for Diagnosis of TB Infection
Learning Objectives Using Interferon Gamma Release Assays for Diagnosis of TB Infection 1. Describe available Interferon Gamma Release Assay tests for TB infection and how they work. 2. Understand interpretation
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Tuberculosis Pathogenesis and Treatment f Latent TB Infection Lynn Horvath, MD October 15, 2013 Lynn Horvath, MD has the following disclosures to make: No
More informationTuberculosis Education for the Medical Professional
Tuberculosis Education for the Medical Professional North Dakota Diagnosis and Medical Management of Latent TB Infection Dawn Farrell, RN, BSN, PHN Maria Robles, BSN July 10, 2007 Tuberculosis Education
More informationTB Intensive. San San Antonio, Texas. December 1-3, 2010
TB Intensive San Antonio, Texas December 1-3, 2010 ATS/CDC Guidelines for Treating Latent TB Infection Timothy Aksamit, MD; Mayo Clinic December 1, 2010 ATS/CDC Guidelines for Treating LTBI Tuberculosis
More informationTherapy for Latent Tuberculosis Infection
Screening and Treatment of LTBI in TB Control in the US Margarita Elsa Villarino MD MPH Division of TB Elimination, CDC April 14, 2004 TB Prevention and Control in the United States The fundamental strategies
More informationTuberculosis Tools: A Clinical Update
Tuberculosis Tools: A Clinical Update CAPA Conference 2014 JoAnn Deasy, PA-C. MPH, DFAAPA jadeasy@sbcglobal.net Adjunct Faculty Touro PA Program Learning Objectives Outline the pathogenesis of active pulmonary
More informationUtility of PPD or IGRA to answer the age old question of "TB or not TB
Utility of PPD or IGRA to answer the age old question of "TB or not TB Thomas S. Alexander, Ph.D., D(ABMLI) Immunologist Summa Health alexandt@summahealth.org Yes, The reservation is in the name of Dr.
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2, 2011 ATS/CDC Guidelines for Treating LTBI Timothy Aksamit, MD April 6, 2011 Timothy Aksamit, MD has the following disclosures to make: No conflict of interests
More information10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas August 2-5, 2011 Pediatric TB Jeffrey Starke, MD August 5, 2011 Jeffrey Starke, MD has the following disclosures to make: Is on a data safety monitoring board for Hoffman
More informationConflict of Interest Disclosures:
Mady Slater, M.D. Stanford University Medical Center Division of Infectious Diseases 04/23/14 WOEMA webinar Conflict of Interest Disclosures: I have no financial relationships with commercial entities
More informationTB Nurse Case Management San Antonio, Texas July 18 20, 2012
TB Nurse Case Management San Antonio, Texas July 18 20, 2012 IGRA s and Their Use in TB Nurse NCM Lisa Armitige, MD, PhD July 18, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationEvaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014
Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014 Interferon Gamma Release Assays: Understanding the Test David Griffith, BA, MD April 11, 2014 David Griffith, BA, MD has the following
More informationDidactic Series. Latent TB Infection in HIV Infection
Didactic Series Latent TB Infection in HIV Infection Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director SF, North Coast and East Bay AETC January 8, 2015 ACCREDITATION
More informationLATENT TUBERCULOSIS. Robert F. Tyree, MD
LATENT TUBERCULOSIS Robert F. Tyree, MD 1 YK TB OFFICERS Ron Bowerman Elizabeth Roll Mien Chyi (Pediatrics) Cindi Mondesir (Pediatrics) The new guys: Philip Johnson Robert Tyree 2009 CDC TB CASE DEFINITION
More informationUnderstanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 What is Latent TB Infection (LTBI)? Traci Hadley, RN October 5, 2010 LTBI or TB Disease? Presented by : Traci Hadley, RN
More informationDiagnosis Latent Tuberculosis. Disclosures. Case
Diagnosis Latent Tuberculosis Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers for Disease Control and Prevention September 2016 1 Disclosures
More informationLatent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers
Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers Who Should Be Screened for Latent Tuberculosis Infection (LTBI)?... 2 What tests are used to screen for LTBI?... 2 How
More informationTB Intensive San Antonio, Texas August 7-10, 2012
TB Intensive San Antonio, Texas August 7-10, 2012 ATS/CDC Guidelines for Treating Latent TB Infection Timothy Aksamit, MD August 7, 2012 Timothy Aksamit, MD has the following disclosures to make: No conflict
More informationTB Intensive Houston, Texas October 15-17, 2013
TB Intensive Houston, Texas October 15-17, 2013 Interferon Gamma Release Assays (IGRA s) Lisa Armitige, MD, PhD October 16, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict
More informationDisclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None
Disclosures Updates in TB for the PCP: Opportunities for Prevention None Pennan Barry, MD, MPH Chief, Surveillance and Epidemiology, California TB Control Branch Assistant Clinical Professor, Division
More informationLTBI: Who to Test & When to Treat
LTBI: Who to Test & When to Treat TB Intensive May 10 th, 2016 David Horne, MD, MPH Harborview Medical Center University of Washington DISCLOSURES I have no disclosures or conflicts of interest to report
More informationTechnical Bulletin No. 172
CPAL Central Pennsylvania Alliance Laboratory QuantiFERON -TB Gold Plus Assay Contact: J Matthew Groeller, MPA(HCM), MT(ASCP), 717-851-4516 Operations Manager, Clinical Pathology, CPAL Jennifer Thebo,
More informationDiagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011 Douglas Hornick, MD has the following disclosures to
More informationDiagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017
Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, 2017 TB Nurse Case Management September 12 14, 2017 EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD has
More informationTB Intensive San Antonio, Texas November 11 14, 2014
TB Intensive San Antonio, Texas November 11 14, 2014 Interferon Gamma Release Assays Lisa Armitige, MD, PhD November 12, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of
More informationEvaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)
Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI) CURTIS FOWLER MPT,PA C ASSISTANT CLINICAL PROFESSOR UNIVERSITY OF THE PACIFIC Learning objectives Recognize the appropriate
More informationBarbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast
Practical Aspects for Using the Interferon Gamma Release Assay (IGRA) Test Live Webinar July 14, 2017 Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and
More informationTB Classification (ATS/CDC)
bits and pieces Lisa Chen, MD UCSF Pulmonary/Critical Care Curry International Tuberculosis Center 10/2017 TB Classification (ATS/CDC) TB0 No tuberculosis exposure, not infected TB1 Tuberculosis exposure,
More informationLatent TB, TB and the Role of the Health Department
Latent TB, TB and the Role of the Health Department Elaine Darnall, RN, BSN, CIC TB Nurse Consultant Illinois Dept of Public Health March 21, 2018 Elaine Darnall has disclosed that there is no actual or
More informationLatent Tuberculosis Best Practices
Latent Tuberculosis Best Practices Last Updated September 7, 2016 LTBI Demographics in the US o 13million people in the US with LTBI (estimate) o In 2014, approximately 66% of TB cases in the United States
More informationLatent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016
Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016 Randy Culpepper, MD, MPH Deputy Heath Officer/Medical Director Frederick County Health Department March 16, 2016 2 No
More informationESCMID Online Lecture Library. by author
Tuberculosis prevention in immunodepressed patients M. Carmen Fariñas Álvarez Infectious Diseases.H.U.Marqués de Valdecilla University of Cantabria, Spain DISCLOSURES I have no potential conflicts with
More informationScreening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:
TB Infection Diagnosis Recommendations Talk Developed by Lisa Y. Armitige, MD, PhD Medical Consultant, Heartland National TB Center Associate Professor Internal Medicine/Pediatrics/Infectious Disease UT
More informationTB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
More informationPre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
More informationInterpretation of TST & IGRA results. Objectives
Interpretation of TST & IGRA results Randall Reves, MD, MSc Volunteer Clinician Denver Metro TB Program and Division of Infectious Diseases, Department of Medicine University of Colorado Denver Objectives
More informationContact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
More informationTUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of
TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of Health and Mental Hygiene TODAY S PRESENTATION Epidemiology
More informationAdvanced Concepts in Pediatric Tuberculosis
Advanced Concepts in Pediatric Tuberculosis: Nizar F. Maraqa, MD, FPIDS Division of Pediatric Infectious Diseases & Immunology University of Florida College of Medicine - Jacksonville Advanced Concepts
More informationThe Most Widely Misunderstood Test of All
The Most Widely Misunderstood Test of All Lee B. Reichman, MD, MPH NJMS Global Tuberculosis Institute History of Treatment of Latent Tuberculosis Infection For more than 4 decades, treatment of persons
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationPeggy Leslie-Smith, RN
Peggy Leslie-Smith, RN EMPLOYEE HEALTH DIRECTOR - AVERA TRAINING CONTENT 1. South Dakota Regulations 2. Iowa Regulations 3. Minnesota Regulations 4. Interferon Gamma Release Assay (IGRA)Testing 1 SOUTH
More informationTB Nurse Case Management
TB Nurse Case Management San Antonio, Texas March 2-4, 2011 Pediatric TB Andrea T. Cruz, MD, MPH March 2, 2011 Andrea Cruz, MD, MPH has the following disclosures to make: No conflict of interests No relevant
More informationPediatric TB Intensive Houston, Texas October 14, 2013
Pediatric TB Intensive Houston, Texas October 14, 2013 LTBI: Screening & Testing Anna M. Mandalakas, MD, MS Epi, FAAP Global Tuberculosis Program Director The Tuberculosis Initiative Texas Children s Hospital
More informationNew Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents
New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents Jeffrey R. Starke, M.D. Professor of Pediatrics Baylor College of Medicine [With great thanks to Andrea
More informationTargeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease
Self-Study Study Modules on Tuberculosis Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease 1 Module 3: Objectives At completion of this module, learners will
More informationInterferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines
Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines Historically, Latent Tuberculosis Infection (LTBI) diagnosis was based on risk assessment, chest x-ray (CXR)
More informationTuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
More informationTesting & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat?
NECHA 11/4/2016 Testing & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat? E. Jane Carter, M.D. Immediate Past President International Union Against TB and Lung Disease
More informationChapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
More informationTB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014
TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014 Catalina Navarro, BSN, RN has the following disclosures to make: No conflict of interests No relevant financial relationships with
More information2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016
Learning Objectives Tuberculosis Case Discussions: Evaluation for Tuberculosis Infection Melissa C. Overman, DO, MPH, CHES, FAOCOPM Describe appropriate technique for TST placement, reading and interpretation
More informationhas the following disclosures to make:
CLINICAL DIAGNOSIS AND MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH September 22, 2015 TB Nurse Case Management September 22 24, 2015 San Antonio. TX EXCELLENCE EXPERTISE INNOVATION Annie Kizilbash
More informationThe Origin of Swine Flu
How the Heck Do You Diagnose Tuberculosis in Children, Anyway? Jeffrey R. Starke, M.D. Professor and Vice Chairman of Pediatrics Baylor College of Medicine Houston, Texas USA The Origin of Swine Flu MAIN
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationThese recommendations will remain in effect until the national shortage of PPD solution has abated.
Maryland Recommendations Regarding the National Shortage of Purified Protein Derivative (PPD) Solution; Attachment to Health Officer Memorandum National Shortages of Tubersol and Aplisol for TB Skin Testing;
More informationDiagnosis and Medical Management of Latent TB Infection
Diagnosis and Medical Management of Latent TB Infection Marsha Majors, RN September 7, 2017 TB Contact Investigation 101 September 6 7, 2017 Little Rock, AR EXCELLENCE EXPERTISE INNOVATION Marsha Majors,
More informationPlease distribute a copy of this information to each provider in your organization.
HEALTH ADVISORY TO: Physicians and other Healthcare Providers Please distribute a copy of this information to each provider in your organization. Questions regarding this information may be directed to
More informationManagement of Pediatric Tuberculosis in New Jersey
Management of Pediatric Tuberculosis in New Jersey Helen Aguila, MD NJMS Global TB Institute December 15, 2011 This presentation is in part adapted from Pediatric Tuberculosis by Ann Loeffler, MD : Francis
More informationTuberculin Skin Testing
Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010 Testing to TB Infection Using the TST Presented by Debra Howenstine, MD for Debbie Onofre, RN October 5, 2010 Tuberculin
More informationPREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal
PREVENTION OF TUBERCULOSIS Dr Amitesh Aggarwal 25 to 50 % of persons exposed to intimate contact with active PTB - latent infection with TB. Exposure to index case for 12 hours - high risk of infection.
More informationLatent Tuberculosis in Adults: From Testing TO Treatment
Latent Tuberculosis in Adults: From Testing TO Treatment Sergio M. Borgia, MD, MSc., FRCP(C) Infectious Diseases Consultant, WOHS Medical Director, WOHS Tuberculosis Clinic Assistant Clinical Professor,
More informationLatent TB Infection (LTBI) Strategies for Detection and Management
Latent TB Infection (LTBI) Strategies for Detection and Management Patrick T. Dowling MD,MPH Professor and Chair Dept of Family Medicine David Geffen School of Medicine at UCLA Pri-Med March 29 2014 Pdowling@mednet.ucla.edu
More informationTB Screening and Diagnosis
TB Screening and Diagnosis Douglas B. Hornick, MD Pulmonologist w/ Infectious Attitude Division of Pulm/Crit Care/Occ Med UI Carver College of Medicine Disclosures: None Objectives Rural (US) TB epidemiology
More informationDiagnosis & Management of Latent TB Infection
Diagnosis & Management of Latent TB Infection Prof. Ashok Rattan, MD, MAMS, INSA DFG, WHO Lab Director Academics, Industry: Research, Diagnosis, Public Health, Academics Adviser: Laboratory Operations,
More informationTuberculosis Populations at Risk
Tuberculosis Populations at Risk One-third of the world is infected with TB, an average of one new infection per second Two million people died from tuberculosis in 2010, 1 every 20 seconds TB is the leading
More informationDIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE
DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE Annie Kizilbash MD, MPH Assistant Professor University of Texas Health Science Center Staff Physician, Texas Center for Infectious Diseases TB Nurse Case
More informationTUBERCULOSIS. Presented By: Public Health Madison & Dane County
TUBERCULOSIS Presented By: Public Health Madison & Dane County What is Tuberculosis? Tuberculosis, or TB, is a disease caused by a bacteria called Mycobacterium tuberculosis. The bacteria can attack any
More informationTUBERCULOSIS. Pathogenesis and Transmission
TUBERCULOSIS Pathogenesis and Transmission TUBERCULOSIS Pathogenesis and Transmission Infection to Disease Diagnostic & Isolation Updates Treatment Updates Pathogenesis Droplet nuclei of 5µm or less are
More informationLATENT TUBERCULOSIS SCREENING AND TREATMENT:
LATENT TUBERCULOSIS SCREENING AND TREATMENT: TB or not TB Christopher Kwong, MD and William Rifkin, MD Week 14 Educational Objectives: 1. Understand who should be screened for latent TB infection and why
More informationScreening and Treatment Recommendations for Persons Exposed to MDR TB
Screening and Treatment Recommendations for Persons Exposed to MDR TB Although all persons at increased risk of tuberculosis (TB) infection should be screened for TB infection per USPTF/CDC guidelines
More informationSelf-Study Modules on Tuberculosis
Self-Study Modules on Tuberculosis Targe te d Te s ting and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control
More informationDiagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015
Diagnosis and Medical Management of TB Disease Quratulian Annie Kizilbash, MD, MPH March 17, 2015 TB Nurse Case Management March 17 19, 2015 San Antonio, Texas EXCELLENCE EXPERTISE INNOVATION Quratulian
More informationINDEX CASE INFORMATION
Instructions for Completing the MDH Tuberculosis Contact Investigation Report Form Please provide as much information as possible. Each field represents information that is important to the contact investigation.
More information11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016
Disclosures Update In Tuberculosis, Indiana 2017 Bradley Allen, MD, PhD, FACP, FIDSA Indiana University School of Medicine Division of Infectious Diseases Roudebush VAMC Indianapolis Medical Consultant,
More information